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In this study, we characterized the viral determinants of coreceptor usage in relation to susceptibility to
antibody-mediated neutralization or enhancement of infectivity by using chimeras of three highly related
human immunodeficiency virus type 1 (HIV-1) isolates of different phenotypes. We found that the V3 region
was the main determinant of antibody-mediated enhancement and coreceptor specificity but that the overall
structure of gp120 was also important for these properties. Constructs susceptible to antibody-mediated
enhancement preferentially use CCR5 as a coreceptor, in contrast to constructs that were neutralized or not
affected. Using monoclonal antibodies directed against CD4 or CCR5, we were able to show that antibody-
mediated enhancement was CD4 dependent. Altogether, our results suggest that the modulation of the
interaction of gp120 with CCR5 is the mechanism underlying antibody-mediated enhancement of HIV-1
infectivity.
Human immunodeficiency virus type 1 (HIV-1) entry into
CD4 cells is initiated by the high-affinity interaction between
the viral envelope glycoprotein and the cell membrane-associ-
ated CD4 molecule. This interaction triggers conformational
changes in gp120, allowing the subsequent binding of the
gp120-CD4 complex to a chemokine receptor (15, 36, 41, 57).
While primary macrophage-tropic HIV-1 isolates use CCR5 as
a coreceptor (R5 isolates), T-cell-line-tropic or laboratory-
adapted strains of HIV-1 can also use other coreceptors, such
as CXCR4 (X4 or R5X4 isolates) (5, 27). Binding to the
coreceptor induces additional conformational changes in
gp120, demasking the fusion complex of gp41 and allowing
fusion between the cellular and viral lipid membranes and
entry of the viral capsid into the target cell (17, 22).
HIV-1 variants can also be distinguished by their sensitivity
to gp120-specific monoclonal antibodies (37). The infectivity of
most primary HIV-1 strains is neutralized or not affected in the
presence of soluble CD4 or monoclonal antibodies directed
against the V3 loop or the CD4-binding domain of gp120. The
mechanism of and the viral determinants involved in HIV-1
neutralization have been studied extensively. HIV-1 neutral-
ization results from the inhibition of virus attachment to the
cell, either by disruption of the gp120-gp41 interaction (shed-
ding) or by steric hindrance or direct inhibition of the entry
process (37, 55). It has been shown that primary HIV-1 strains
are less sensitive to shedding than laboratory-adapted strains
(11, 18, 31), and HIV-1 susceptibility to neutralization appears
to be mainly determined by the overall structure of the enve-
lope glycoprotein (34, 35, 38).
In contrast, the infectivity of some primary HIV-1 strains is
enhanced by gp120-specific monoclonal antibodies or soluble
CD4 under the same conditions (45, 51), but little is known
about the mechanisms of antibody-mediated enhancement of
HIV-1 entry. The process has been shown to be independent of
Fc or complement receptors and to be temperature indepen-
dent, while the involvement of cross-linking between gp120
subunits remains controversial (45, 50). The V3 loop has been
suggested as the main viral determinant for antibody-mediated
enhancement in cooperation with other domains of gp120 (50).
So far, this characteristic has been shown only for one HIV-1
clone, and the level at which the entry process is affected by
antibody-mediated enhancement is still unidentified.
Here, we studied three closely related HIV-1 envelopes,
16.1, 16.2, and 16.4, isolated from the same patient (1). Syn-
cytium-inducing (SI) variants 16.1 and 16.2 were unaffected
and neutralized, respectively, when preincubated with gp120-
specific monoclonal antibodies, whereas the infectivity of non-
syncytium-inducing (NSI) variant 16.4 was enhanced under the
same conditions (45, 46). Using chimeras of these three enve-
lopes, we studied the viral determinants of antibody-mediated
enhancement and the influence of antibodies directed against
CD4 and CCR5 on the entry process. We found that antibody-
mediated enhancement of infectivity depends on the structure
of the gp120 protein and that it involves the modulation of the
interaction of gp120 with CCR5 but not with CXCR4.
MATERIALS AND METHODS
Envelope genes. The parental envelope genes were amplified from three bio-
logical clones, 16.1, 16.2, and 16.4, isolated from the same patient and cloned in
expression vector pSHRS (1, 2, 14). Chimeric envelope genes were generated by
using previously described restriction sites (1) and are shown in Fig. 1. Constructs
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were checked by restriction analysis and/or automatic sequencing by using cus-
tom oligonucleotides and a dye-deoxy terminator sequencing kit (Perkin-Elmer).
Cells. SupT1 and COS cells were cultured in RPMI medium supplemented
with 10% fetal calf serum (FCS) and antibiotics. A panel of U87.CD4 cells, stably
transfected with human CD4 and different chemokine receptors (23) (kindly
provided by D. Littman), was cultured in Dulbecco modified Eagle medium
(DMEM)–10% FCS. The expression of the transgenes was regularly selected for
with 1 mg of Geneticin (Gibco-BRL)/ml and 0.1 g of puromycin (Calbiochem)/
ml. CD4 expression was assessed regularly by FACScan analysis.
Generation of Env-pseudotyped viruses. Five to 10 million COS cells were
electroporated at 220 V and 960 F in serum-free RPMI medium with 10 g of
pSHRS expressing HIV-1 envelopes and 10 g of an Env-deleted HIV-1 mo-
lecular clone containing the chloramphenicol acetyltransferase (CAT) reporter
gene as described previously (2, 21). Three days after transfection, supernatants
containing Env-pseudotyped viruses were harvested, stored at 70°C, and used
for coreceptor studies or neutralization assays.
Coreceptor usage assay. One day before infection, U87.CD4 cells expressing
chemokine receptors were plated in six-well plates (Costar) at 2  105 cells per
well. On the next day, medium was removed from the cells and infection was
performed in parallel for cells expressing the second receptor for 8 to 16 h with
Env-pseudotype viruses in a final volume of 750 l. Cells were washed once and
cultured for 2 to 3 days in DMEM–10% FCS. Cell pellets were collected and
analyzed for CAT activity as described previously (2, 48). The relative efficiency
of CXCR4 usage was determined for each experiment as the ratio of CAT
activity of CXCR4-expressing cells to CAT activity of CCR5-expressing cells in
the same experiment. The nomenclature of viruses was based on previously
defined criteria (12).
Neutralization enhancement assay. The neutralization enhancement assay was
performed as previously described (45). Briefly, Env-pseudotyped viruses were
preincubated with or without 15 g of V3 loop-specific antibody 391/95-D (a
kind gift from S. Zolla-Pazner) for 30 to 45 min at 37°C in a final volume of 500
l. Two million SupT1 cells were added to the virus-antibody mixture (or to the
virus alone) and incubated overnight at 37°C in a final volume of 1 ml. Cells were
washed, cultured in 3 ml of RPMI medium–10% FCS for 2 to 3 days, lysed, and
analyzed for CAT activity. The change in infectivity caused by the antibody was
determined for each experiment as the ratio of CAT activity in the presence of
antibody 391/95-D to CAT activity in the absence of antibody.
Cellular receptor requirements. CD4-specific monoclonal antibodies L120.3,
Q425, Q4120, 13B8-2, JAH 7.3F11, and RFT4 (kindly provided by Q. Sattentau)
are directed against the CD4 receptor: Q4120, 13B8-2, JAH 7.3F11, and RFT4
bind to domain 1, Q425 is directed against domain 2, and L120.3 is directed
against domain 4 of the CD4 molecule (20, 43, 56). All these antibodies, except
for L120.3, have been shown to inhibit HIV-1 infection by interfering with
gp120-CD4 binding (Q4120, 13B8-2, and JAH 7.3F11) and/or inhibiting syncy-
tium formation (Q425, Q4120, 13B8-2, JAH 7.3F11, and RFT4) (10, 20, 56). Two
million SupT1 cells were preincubated with 10 g of monoclonal antibodies/ml
(or 10 l of ascitic fluid per ml of cells) for 30 to 45 min at 37°C and further
processed as described for the neutralization enhancement assay.
The mouse immunoglobulin G3 anti-CCR5 antibody 2D7 was purchased from
Pharmingen and was previously shown to inhibit HIV-1 entry by blocking the
gp120-CCR5 interaction (16, 59). Infection of U87.CD4 cells expressing CCR5
(U87.CD4-CCR5 cells) was performed for 4 h in the presence of serial dilutions
of this antibody in DMEM–10% FCS. Cells were washed and further processed
as described for the coreceptor usage assay.
RESULTS
Viral determinants of antibody-mediated enhancement of
16.4. By use of chimeras of 16.1, 16.2, and 16.4, it was previ-
ously shown that antibody-mediated neutralization or en-
hancement was determined by the gp120 but not the gp41
subunit of the HIV-1 envelope protein (46). Although CCR5 is
not efficiently expressed by SupT1 cells, the level of expression
is sufficient to sustain infection by R5 isolate 16.4. Here, we
generated various chimeric envelopes by exchanging domains
FIG. 1. Antibody-mediated modulation of entry of various chimeric viruses. (Left) Schematic representation of chimeric constructs. S, SpeI; H,
HindII; C, CvnI; B, BspLU11I; M, MamI; A, AvrII. (Middle) Efficiency of entry into SupT1 cells for viruses pseudotyped with different constructs
after 30 to 45 min of preincubation with 15 g of V3 loop-specific antibody 391/95-D/ml. The broken line at 100% indicates no effect. Values
represent the mean of at least three different experiments. (Right) Basal level of entry of the various chimeras, as indicated by the CAT activity
observed for each construct in the absence of monoclonal antibody.
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of gp120 of 16.4 with those of 16.1 or 16.2 and characterized
the sensitivity of the resulting chimeras to antibody-mediated
modulation of entry by using the V3 loop-specific antibody
391/95-D. As shown in Fig. 1, the introduction of the V3 region
of 16.4 into 16.1 or 16.2 (41HC or 42HC, respectively) resulted
in chimeric envelopes that could be enhanced. Separate intro-
duction of the V1-V2 region or the V4-C5 region of 16.4 into
16.2 (42XS or 42CA, respectively) was not sufficient to transfer
enhancement, but the chimera containing both regions (24HC)
was enhanced under these conditions (Fig. 1). The introduc-
tion of any single domain of 16.1 or 16.2 into the 16.4 back-
ground was not sufficient to induce antibody-mediated neutral-
ization (14HC, 24XS, 24HC, and 24CA) (Fig. 1). However, the
introduction of a single mutation (E439K) from the C4 domain
of 16.4 into the background of 16.1 was sufficient to change the
phenotype from unaffected to neutralized (41BM) (Fig. 1).
FIG. 2. Impact of antibody-mediated enhancement on the usage of cellular receptors by 16.4. (A) Effect of a CD4-specific antibody on
antibody-mediated enhancement of infectivity. The values represent the percentage of entry of pseudotyped viruses into SupT1 cells relative to
values obtained without preincubation of the cells with the CD4-specific antibody. For preincubation, 391/95-D was used at 15 g/ml. N.T., not
tested. (B) Coreceptor usage of the three parental clones in the absence of gp120-specific monoclonal antibodies. Values are representative of at
least three different experiments. (C) Impact of V3 loop-specific antibody 391/95-D on the infectivity of 16.4. Pseudotyped virus was preincubated
or not preincubated with 15 g of 391/95-D/ml prior to infection of U87.CD4 cells. Values are representative of four different experiments.
VOL. 76, 2002 ANTIBODY-MEDIATED ENHANCEMENT AND CORECEPTOR USAGE 2829
These results suggest that antibody-mediated modulation of
entry is determined by multiple domains within gp120.
The same experiments performed with monoclonal antibody
GP68, directed against the CD4-binding site of gp120 (47),
gave similar results (data not shown), indicating that the en-
hanced or neutralized phenotype is determined by the enve-
lope conformation independently of the specificity of the anti-
gp120 antibody.
Cellular receptor used during antibody-mediated enhance-
ment. We determined whether antibody-mediated enhance-
ment of 16.4 was associated with a CD4-independent pathway
of entry, as has been shown for HIV-2 (8, 39, 40). For this
purpose, we used a panel of six CD4-specific antibodies, five of
which (RFT-4, JAH 7.3F11, Q4120, 13B8-2, and Q425) were
shown to efficiently inhibit the interaction of CD4 with HIV-1
gp120 and one of which (L120.3) did not influence HIV-1
entry. We investigated the effect of preincubation of SupT1
cells with these CD4-specific antibodies on the efficiency of
entry of 16.4 in the presence or absence of the V3 loop-specific
antibody 391/95-D. Figure 2A shows that preincubation of 16.4
with 391/95-D did not overcome the block of entry by the
different CD4-specific antibodies. The fact that CD4-specific
antibodies block the infectivity of 16.4 to the same extent in the
presence or absence of V3 loop-specific antibodies indicates
that antibody-mediated enhancement does not modulate the
interaction between CD4 and the gp120 glycoprotein.
Antibody-mediated enhancement may be the result of the
use of an alternative coreceptor. In agreement with previous
reports (5, 27), 16.1 and 16.2 were able to enter U87.CD4-
CCR5 cells or U87.CD4 cells expressing CXCR4 (U87.CD4-
CXCR4 cells), whereas the NSI clone 16.4 could enter only
U87.CD4-CCR5 cells (Fig. 2B). We next compared the core-
ceptors used by 16.4 in the absence or presence of the V3
loop-specific antibody 391/95-D. As shown in Fig. 2C, the ad-
dition of the V3 loop-specific antibody did not result in a
change in the spectrum of coreceptor usage by 16.4. A high
multiplicity of infection was used to allow the detection of
low-efficiency use of an alternative coreceptor(s). This strategy
resulted in saturating CAT activities in both the presence and
the absence of the V3 loop-specific monoclonal antibody (Fig.
2C). As a result, enhancement was not detected in this exper-
iment, but enhancement was detected at a lower multiplicity of
infection (data not shown).
Interaction between gp120 and CCR5 during antibody-me-
diated enhancement. Next, we tested whether antibody-medi-
ated enhancement of 16.4 infectivity could be explained by a
difference in the interaction between gp120 and CCR5. There-
fore, 16.4 pseudotypes were preincubated with or without the
V3 loop-specific antibody 391/95-D before infection of
U87.CD4-CCR5 cells in the presence of serial dilutions of the
CCR5-specific monoclonal antibody 2D7. Figure 3 shows that
the inhibition of infection by 2D7 was concentration depen-
dent at between 0.1 and 50 g/ml. In this range, the amount of
2D7 needed to inhibit the entry of 16.4 was significantly lower
(P  0.02; Student’s t test) when the 16.4 envelope was prein-
cubated with the V3 loop-specific antibody 391/95-D. At lower
concentrations of 2D7 (between 0.01 and 0.1 g/ml), concen-
tration-dependent inhibition of infectivity was still observed for
untreated 16.4, while the infectivity of 16.4 preincubated with
391/95-D was enhanced. The finding that the pretreatment of
16.4 gp120 by an anti-envelope antibody modifies its infectivity
in the presence of an anti-CCR-5 antibody suggests that the
antibody-mediated enhancement of infectivity of 16.4 results
from modulation of the interaction between gp120 and CCR5.
Coreceptor usage of chimeric viruses. We next tested our
panel of chimeric viruses with U87.CD4-CCR5 or U87.CD4-
CXCR4 cells to determine which domains of 16.1 and 16.2
were involved in the ability to use CXCR4 as a coreceptor. The
FIG. 3. Impact of a CCR5-specific antibody on antibody-mediated enhancement of 16.4 infectivity. Values represent intracellular CAT activity
after infection of U87.CD4-CCR5 cells in the presence of serial dilutions of CCR5-specific antibody 2D7. Values represent the mean for two
different experiments; error bars indicate standard deviations. Regression curve determinations and Student’s t test were performed by using the
tools of SigmaPlot 5.0 software.
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entry of chimeric viruses into U87.CD4 cells expressing
CCR-1, CCR-2b, CCR-3, or no coreceptor was never observed
(data not shown). As shown in Fig. 4, the introduction of any
domain of an R5X4 clone into the 16.4 (R5 only) background
led to entry into U87.CD4-CXCR4 cells, although at different
efficiencies. In particular, the introduction of the V3 loop of
16.1 or 16.2 into 16.4 (14HC or 24HC, respectively) (Fig. 4)
resulted in an efficient use of CXCR4. In contrast, the intro-
duction of the V3 loop of 16.4 into an R5X4 background
(41HC and 42HC) only moderately influenced the usage of
CXCR4. Independent transfer of the V1-V2 region or the
N-terminal part of 16.2 into 16.4 resulted in chimeras with a
very low capacity to enter CXCR4-expressing cells (24XS or
24CA, respectively) (Fig. 4), while the chimera containing both
domains (42HC) efficiently used CXCR4. These results sug-
gests that the V3 loop is the main determinant used by clones
16.1 and 16.2 to enter CXCR4-expressing cells but that inter-
actions between other domains outside the V3 loop are also
involved in CXCR4 usage.
Inverted correlation between antibody-mediated enhance-
ment and CXCR4 usage. Since the same regions of the enve-
lope are involved in determining the effects of antibodies on
the entry of HIV-1 and on coreceptor usage, we compared the
different chimeric viruses with respect to these properties. For
this purpose, we divided all the constructs into three categories
depending on their sensitivity to neutralization or enhance-
ment by the V3 loop-specific antibody. Chimeras were consid-
ered to be significantly neutralized when their infectivity was
inhibited more than 50% by the V3 loop-specific antibody (13)
and to be significantly enhanced when their infectivity was
increased by a factor of 2 or more under the same conditions.
The third category contained all the chimeras that were not
affected or were moderately affected (between 50 and 200%
the control). A clear correlation between antibody-mediated
enhancement and coreceptor usage existed: chimeras that
were enhanced by 391/95-D used CXCR4 less efficiently than
chimeras that were neutralized or unaffected (Fig. 5). No sig-
nificant difference in the relative efficiency of CXCR4 usage
was observed between chimeras that were efficiently neutral-
ized by gp120 antibodies and chimeras whose infectivity was
not significantly affected.
DISCUSSION
In this study, we used chimeric viruses of three related
HIV-1 variants to identify the viral determinants of coreceptor
usage and antibody-mediated modulation of HIV-1 infectivity.
Upon interaction with CD4 and the appropriate chemokine
receptor, the HIV-1 envelope glycoprotein oligomer under-
goes conformational changes that create the optimal structure
for the subsequent steps of the fusion process (6, 44). The
recent characterization of the gp120 crystal structure (28, 41,
59) has suggested that these conformational changes are dic-
tated by the interaction between the V1-V2 and C4 domains,
forming the so-called “bridging sheet.” In this model, the exact
involvement of the V3 loop was not determined, but it has
FIG. 4. Relative efficiency of CXCR4 usage of various chimeric viruses. (Left) Schematic representation of chimeras. See the legend to Fig. 1
for details. (Middle) Relative efficiency of entry into U87.CD4-CXCR4 cells compared to that for U87.CD4-CCR5 cells. Values represent the
mean of at least three different experiments. (Right) Basal level of entry of the various chimeras, as indicated by the CAT activity observed for
each construct.
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been suggested to be the domain that interacts directly with the
chemokine receptor (7, 52).
For HIV-2, enhancement of infectivity has been associated
with a CD4-independent, CXCR4-dependent pathway of entry
(39, 40). However, the mechanism is probably different for
HIV-1, since antibody-mediated enhancement of 16.4 entry
was CD4 dependent and entry did not occur via an alternative
coreceptor. Dose-dependent inhibition of entry of 16.4 in the
absence or presence of a V3 loop-specific antibody was ob-
served for concentrations of 2D7 above 0.1 g/ml, which have
been shown to completely inhibit the binding of monomeric
gp120-CD4 complexes to CCR5 (58). However, we could still
detect infection with 2D7 concentrations of up to 10 g/ml,
suggesting an incomplete inhibition of binding of oligomeric
gp120 to CCR5 under these conditions. In this range of 2D7
concentrations, preincubation of 16.4 with an anti-gp120
monoclonal antibody increased susceptibility to inhibition of
entry by 2D7. This result suggests that, in contrast to the results
of a previous study (50), the binding of a V3 loop-specific
monoclonal antibody to an Envelope that is enhanced modifies
the subsequent gp120-CCR5 interaction. This apparent dis-
crepancy may be related to experimental conditions, and ad-
ditional experiments are needed to verify this point.
We observed that infection in the presence of low concen-
trations of CCR5-specific antibody 2D7 was 30 to 40% more
efficient than that in the absence of 2D7 for 16.4 preincubated
with a V3 loop-specific antibody. This phenomenon was ob-
served only for 2D7 concentrations of 0.01 to 0.1 g/ml when
the binding of monomeric gp120-CD4 complexes to CCR5-
expressing cells was only partially inhibited (58). This phenom-
enon could be related to the enhancement of infectivity trig-
gered by low concentrations of RANTES protein, a natural
ligand for CCR5 (53). The fact that we observed this phenom-
enon with 16.4 only when it was preincubated with an anti-
gp120 antibody suggests that it is specific for a certain confor-
mation of the envelope protein. This mechanism could result
from the induction of a conformational change or multimer-
ization of CCR5 and/or the triggering of an intracellular signal
(4, 19, 30), but the determination of its molecular basis re-
quires further investigations. In parallel, we could also show
that antibody-mediated neutralization of entry was determined
by the overall structure of gp120 but was independent of co-
receptor usage, in accordance with previous results (29, 33, 54).
In accordance with previous reports (5, 27, 49), our experi-
ments showed that SI clones 16.1 and 16.2 are R5X4 viruses
(using both CXCR4 and CCR5 as coreceptors), while NSI
clone 16.4 is an R5 virus. Interestingly, the introduction of any
domain from an SI, R5X4 clone into NSI, R5 clone 16.4 cre-
ates chimeras able to use CXCR4 as a coreceptor, although
with various efficacies. That the same exchanges were previ-
ously shown to create chimeras that were all able to induce
syncytia in vitro (2) substantiates previous reports of a corre-
lation between CXCR4 usage and SI capacity (5). This ability
to easily switch from an R5 to an R5X4 phenotype in our
constructs can also be related to reports showing that the
coreceptor usage of the variants present in infected individuals
evolves over time: patients harbor only R5, macrophage-tropic
variants at early stages, and progression toward AIDS is asso-
ciated with the appearance of R5X4 variants (5, 9). Moreover,
CCR5 appears to be the most important coreceptor for HIV-1
in vivo (32, 42). Furthermore, strong conservation of amino
acid sequences in early NSI, R5, macrophage-tropic isolates
can be observed (25). Finally, NSI, R5 viruses harbor a more
stable structure for the V3 loop than SI viruses (24).
One model which could fit with our data and the above
observations is that the stability of the envelope structure is
crucial for determining phenotypic properties such as corecep-
tor usage or SI capacity. In this view, mutations or domain
swapping in an NSI, R5 gp120 protein is likely to perturb its
stability, and the resulting relaxed structure would allow
CXCR4 usage and syncytium induction. Thus, both properties
are unlikely to represent a gain of function for the envelope
protein. This view also suggests that the susceptibility of anti-
body-mediated enhancement of infectivity, although a charac-
teristic of NSI, CCR5 viruses, is not directly dependent on the
stability of the envelope protein, since this phenotype is not
changed by domain swapping in gp120. The property is there-
fore more likely to be a consequence of gp120 folding itself,
where domains of the envelope protein interacting with cellu-
lar receptors are cryptic and exposed only after the binding of
monoclonal antibodies.
Because HIV-1 variants susceptible to antibody-mediated
enhancement would benefit from the immune response of the
patient, this phenomenon may have a role during HIV-1 in-
fection. This notion is corroborated by the observations that up
to 28% of combinations of sera and primary HIV-1 isolates
obtained directly from patients caused serum-dependent infec-
tivity enhancement and that this phenomenon was specific for
the viral isolate (3, 26), as confirmed in the present study.
However, the overall infectivity of variants susceptible to an-
tibody-mediated enhancement is probably poor in the absence
of gp120-specific antibodies. Only in the presence of Env-
specific antibodies did these isolates reach levels of infectivity
comparable to those of isolates that were not enhanced (46).
This scenario may explain why only a few isolates have been
FIG. 5. Correlation between antibody-mediated modulation of en-
try and efficient CXCR4 usage. The box plot was generated by using
SigmaPlot 5.0 software and the paired data of Fig. 1 and 4 for each
virus or chimera tested. Error bars indicate standard deviations.
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identified that are susceptible to antibody-mediated enhance-
ment, because these viruses will be outgrown rapidly during in
vitro culturing in the absence of gp120-specific antibodies. It is
therefore relevant to further investigate viruses isolated with-
out in vitro culturing steps for their role in the establishment of
a chronic infection during seroconversion.
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